Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
- 1 November 2007
- journal article
- review article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 7 (11), 733-738
- https://doi.org/10.1016/s1473-3099(07)70262-1
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Prediction of Neuropsychiatric Adverse Events Associated with Long-Term Efavirenz Therapy, Using Plasma Drug Level MonitoringClinical Infectious Diseases, 2005
- Should Non-Nucleoside Reverse Transcriptase Inhibitors be Combined?Drugs in R&D, 2005
- Antiretrovirals, Part II: Focus on Non-Protease Inhibitor Antiretrovirals (NRTIs, NNRTIs, and Fusion Inhibitors)Psychosomatics, 2004
- Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyThe Lancet, 2004
- Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitorsHIV Medicine, 2004
- Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rashAIDS, 2002
- HIV and drug allergyCurrent Opinion in Allergy and Clinical Immunology, 2001
- Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patientsAIDS, 2001
- Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?AIDS, 2000
- EfavirenzDrugs, 1998